AKT1 and neoplasm: Dual targeting to inhibit AKT phosphorylation while activating p38 MAPK can block autophagosome-lysosome fusion, enhancing paclitaxel chemosensitivity, suppressing tumor proliferation, metastasis, and stemness, and mitigating toxicity associated with traditional autophagy inhibitors [71].